Fighting Cancer
with Precision Innovation
The technology to
detect & treat cancer.
The clinical experience
to know how.
The dedication to
improve lives.
Next-generation Oncology Products
NuView Life Sciences is a clinical-stage radiopharmaceutical company developing next-generation oncology products to address the growing need for radiopharmaceuticals in cancer diagnosis and therapy.
We are a global leader in paired radiopharmaceuticals for Theranostics, developed with our proprietary small molecule, NV-VPAC1. The next-generation disruptive platform in radiopharmaceuticals employs the "pairing" of Copper-64 (Cu-64) and Copper-67 (Cu-67) for mapping out cancer in the body and treating it.
NV-VPAC1 delivers a compelling combination of high accuracy and high precision in treating various cancer indications and provides supply and logistical advantages over current Theranostics. Our Targeted Copper Theranostics (TCT) provides a highly productive, scalable, and cost-effective way to expand radiopharmaceuticals into the global oncology market.
Our commitment to addressing the diverse needs of the oncology field is evident in its extensive range of products currently in clinical trials. These products are designed to tackle prostate, bladder, and breast cancer, as well as rare indications such as brain and pancreatic cancers, showcasing our comprehensive approach to cancer care.
The versatility of the NV-VPAC1 technology platform enables us to pursue a program focused on developing new oncology products and new intellectual property (IP) for a range of cancer indications. NuView has a robust IP position with a broad patent portfolio covering its platform, pipeline, and in vitro and in vivo products.
NV-VPAC1 is the key to imaging the precise location and extent of tumor mestasis
- GPCRs is the largest known class of membrane receptors in the human body
- 30-50% of all modern medicinal drugs are focused on GPCRs
- VPAC1 receptors are a well-known subtype of GPCRs
- NV-VPAC1 binds to the overexpression of VPAC1 receptors for in vitro or in vivo diagnosis of cancer cells, which allows a means of tumor imaging of the location and extent of the tumor mestasis
- NV-VPAC1 mechanism of action allows for targeted treatment by coupling cytotoxic agents (radiation, chemotherapy, to NV-VPAC1)
NV-VPAC1™ Lab Assays
Diagnostics
A proprietary small molecule targeting a subfamily of G-protein-coupled Receptors (GPCRs) called Vasoactive Intestinal Polypeptide Receptor 1 (VPAC1) for in vitro or in vivo cancer applications.
NuView's in vitro diagnostic lab assay pairs our small molecule with a fluorophore to accurately detect cancer cells in biofluids. It avoids genetic tests and eliminates the discomfort of surgical biopsy and unnecessary medical procedures.
NuView's diagnostic imaging compound for Positron Emission Tomography (PET/PET-CT/PET-MRI) utilizing a Copper-64 (Cu-64) positron emitter localizes all sites of GPCRs.
VPAC1 cancers in soft tissue, bone, and lymph nodes to accurately guide biopsy and targeted therapeutic processes.
Pairing radiopharmaceuticals Cu-64 for diagnostics and Copper-67 (Cu-67) for Theranostic applications
Liquid Biospy: At the 2024 American Association for Cancer Research annual meeting last month, the program was chock full of studies and sessions where liquid biopsies dominated the discourse. There were studies of tests that analyze blood, urine, and saliva for free-floating bits of tumor DNA or RNA, exosomes, and extracellular vesicles. Some of these tests are designed to try to identify cancer at its earliest stages, some to predict whether a patient might respond to a given therapy, and still others to monitor people undergoing treatment to see if it’s working.
Common to all liquid biopsies is that they offer ways of using body fluids to obtain critical information about a person’s cancer without resorting to invasive procedures like surgery to get a sample of a tumor.
Targeted Therapy
- Thomas Jefferson University Developed Technology
- Advancing Cancer Diagnostics and Theranostics
- Proprietary small molecule targets GPCR-emitted cancers
- Modular platform allows the use of our product for laboratory assays and radiotheranostics using positron-emitters, alpha or beta emitters
- Extensive pipeline moving multiple products into clinical development
- Innovative Approach, Immense Opportunities
- NuView's platform technology influences the way a variety of cancers are diagnosed and treated by targeting a specific receptor for precision molecular in vivo or in vitro diagnostics and targeted therapies
- NuView Innovative Platform for Precision Diagnostics and Theranostics
No Direct Competitors
- Unique Business Opportunity
- Proprietary small molecule specifically targeting GPCR/VPAC1
IN VITRO AND IN VIVO BINARY DIAGNOSTIC SYNERGIES
- In vitro and in vivo binary lab assay detects cancer cells in biospecimens
- Radiodiagnostic offers in vivo binary imaging of cancer cells and targeted therapy
PRECISION THERAPEUTIC DELIVERY
- Our Radiotherapeutic precisely delivers treatment directly to diagnosed cancer cells
- Targets the overexpression of VPAC1 receptors only found in cancer cells
OPTIMIZED PATIENT TREATMENT PLANNING AND DELIVERY
- Radiodiagnostic imaging predetermines the location of VPAC1 cancer cells for personalized, targeted therapy
- Enables localization of primary and metastasized cancer cells in soft tissue, bone, lymphatic systems
PATIENT-CENTRIC
- Our platform technology provides a continuum for improved patient diagnosis
- Enhances AI, 3D diagnostic imaging, and response to therapy
NVLS Products
In Vitro Diagnostics
AN IN VITRO DIAGNOSTIC KIT THAT MAY BE USED FOR DETECTING SHED PROSTATE AND BLADDER CANCER CELLS IN VOIDED URINE
In Vivo Diagnostics
A POSITRON EMISSION
TOMOGRAPHY (PET) IMAGING
AGENT FOR THE IN VIVO
DIAGNOSIS OF BREAST AND
PROSTATE CANCER
Theranostics
NuView is preparing to expand its portfolio for Theranostics applications using the NV-VPAC1 peptide analog...
NVLS Management Team
Together, they are furthering NuView Life Science’s mission: to change the way many types of cancer are diagnosed and treated using precision medicine technology. Diagnosing and treating cancer with a targeted, specific approach to the disease will help to increase positive patient outcomes while also driving down costs incurred by patients, healthcare providers, and third-party insurance payers. See Full Team
NVLS IN the NEWS
Research Article
Benign prostatic hyperplasia (BPH) is a ubiquitous condition that inflicts millions of males worldwide. BPH has been diagnosed histolog-ically in nearly 50% of men 50–60 years of age and nearly 70% of men 60–70. read more
Research Article
Malignant glioblastoma (MG) is the most common primary tumor of the cerebral hemisphere [1]. Glioblastoma multiforme, among them, is highly malignant and present poor prognosis. Despite the advances in treatment of MG, the disease remains largely incurable [2, 3].
read more
